The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not ...

The Sackler family, owners of Purdue Pharma, reached a $7.4 billion settlement to resolve mass opioid litigation. The Department of Justice filed a civil lawsuit against Walgreens over allegations it ...

Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven’t responded to oral ...

On the company’s Q4 earnings call where an eyepopping $88.8 billion in full-year sales were revealed, leaders shifted focus ...

Analysts discuss Johnson & Johnson's outlook, highlighting MedTech challenges, litigation risks, pipeline opportunities, and mixed performance across segments.

The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...

A nasal spray therapy for treatment-resistant major depressive disorder (MDD) has now been approved by the Food and Drug ...

Overall, women with MS have a 26% increased risk of mental illness during pregnancy and a 33% increased risk after giving birth, compared to women without the degenerative nerve disease.

The Trump administration ordered an immediate pause on public communications from federal health agencies like the CDC, FDA, ...

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

A one-time nasal spray has been approved by the Food and Drug Administration as a standalone treatment for depression.

"Treatment-resistant depression can be very complicated, especially for patients who do not respond to oral antidepressants ...